The lung microbiome in end-stage Lymphangioleiomyomatosis

Lymphangioleiomyomatosis (LAM) is a progressive cystic lung disease with mortality driven primarily by respiratory failure. Patients with LAM frequently have respiratory infections, suggestive of a dysregulated microbiome. Here we demonstrate that end-stage LAM patients have a distinct microbiome si...

Descripción completa

Detalles Bibliográficos
Autores principales: Ng, Julie, Pacheco-Rodriguez, Gustavo, Begley, Lesa, Huang, Yvonne J., Poli, Sergio, Perrella, Mark A., Rosas, Ivan O., Moss, Joel, El-Chemaly, Souheil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8549264/
https://www.ncbi.nlm.nih.gov/pubmed/34702264
http://dx.doi.org/10.1186/s12931-021-01873-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8549264/
https://www.ncbi.nlm.nih.gov/pubmed/34702264
http://dx.doi.org/10.1186/s12931-021-01873-y

Ejemplares similares